Last reviewed 2026-04-20 · How we verify

Furazolin (FURALTADONE)

Phase 2 active Small molecule

Furazolin (generic name: FURALTADONE) is a furaltadone drug. It is currently in Phase 2 development.

Furazolin works by inhibiting the activity of Mitogen-activated protein kinase 9 (MAPK9), a protein involved in cell signaling pathways.

Furazolin, also known as Furaltadone, is a small molecule drug that targets Mitogen-activated protein kinase 9 (MAPK9). It belongs to the furaltadone class and its mechanism of action is not well-documented. There is limited information available on its commercial status, approved indications, and pharmacokinetic properties. Further research is needed to understand its potential therapeutic applications and safety profile. As a result, it is not clear if Furazolin is patented or available as a generic medication.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FURALTADONE
Drug class	furaltadone
Target	Mitogen-activated protein kinase 9
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of cell signaling like a messenger system. MAPK9 is a key messenger that helps cells respond to stress and inflammation. By blocking MAPK9, Furazolin may help reduce inflammation and other symptoms associated with certain diseases.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Furazolin CI brief — competitive landscape report
Furazolin updates RSS · CI watch RSS

Frequently asked questions about Furazolin

What is Furazolin?

Furazolin (FURALTADONE) is a furaltadone drug.

How does Furazolin work?

Furazolin works by inhibiting the activity of Mitogen-activated protein kinase 9 (MAPK9), a protein involved in cell signaling pathways.

What is the generic name of Furazolin?

FURALTADONE is the generic (nonproprietary) name of Furazolin.

What drug class is Furazolin in?

Furazolin belongs to the furaltadone class. See all furaltadone drugs at /class/furaltadone.

What development phase is Furazolin in?

Furazolin is in Phase 2.

What does Furazolin target?

Furazolin targets Mitogen-activated protein kinase 9 and is a furaltadone.

Drug class: All furaltadone drugs
Target: All drugs targeting Mitogen-activated protein kinase 9
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing